Evidence map›Paper›PMID 29396409›Full record

ArticleScientific reports2018

Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue.

M J A Weerts, E C Timmermans, R H A M Vossen, D van Strijp, M C G N Van den Hout-van Vroonhoven, W F J van IJcken, P J van der Zaag, S Y Anvar, S Sleijfer, J W M Martens

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Mitochondrial DNA variation and cancer.Nature reviews. Cancer · 2021
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

M J A WeertsDepartment of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. m.weerts@erasmusmc.nl.
E C TimmermansPhilips Research Laboratories, High Tech Campus 11, 5656 AE, Eindhoven, The Netherlands.
R H A M VossenLeiden Genome Technology Center (LGTC), Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
D van StrijpPhilips Research Laboratories, High Tech Campus 11, 5656 AE, Eindhoven, The Netherlands.
M C G N Van den Hout-van VroonhovenCenter for Biomics, Erasmus MC, Rotterdam, The Netherlands.
W F J van IJckenCenter for Biomics, Erasmus MC, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-0421-8301
P J van der ZaagPhilips Research Laboratories, High Tech Campus 11, 5656 AE, Eindhoven, The Netherlands.ORCID http://orcid.org/0000-0001-9080-4907
S Y AnvarLeiden Genome Technology Center (LGTC), Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
S SleijferDepartment of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
J W M MartensDepartment of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-3428-3366
Erasmus MC Cancer Institute · NLNXP (Netherlands) · NLErasmus MC · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large variation exists in mitochondrial DNA (mtDNA) not only between but also within individuals. Also in human cancer, tumor-specific mtDNA variation exists. In this work, we describe the comparison of four methods to extract mtDNA as pure as possible from frozen tumor tissue. Also, three state-of-the-art methods for sensitive detection of mtDNA variants were evaluated. The main aim was to develop a procedure to detect low-frequent single-nucleotide mtDNA-specific variants in frozen tumor tissue. We show that of the methods evaluated, DNA extracted from cytosol fractions following exonuclease treatment results in highest mtDNA yield and purity from frozen tumor tissue (270-fold mtDNA enrichment). Next, we demonstrate the sensitivity of detection of low-frequent single-nucleotide mtDNA variants (≤1% allele frequency) in breast cancer cell lines MDA-MB-231 and MCF-7 by single-molecule real-time (SMRT) sequencing, UltraSEEK chemistry based mass spectrometry, and digital PCR. We also show de novo detection and allelic phasing of variants by SMRT sequencing. We conclude that our sensitive procedure to detect low-frequent single-nucleotide mtDNA variants from frozen tumor tissue is based on extraction of DNA from cytosol fractions followed by exonuclease treatment to obtain high mtDNA purity, and subsequent SMRT sequencing for (de novo) detection and allelic phasing of variants.

Indexed as

Breast NeoplasmsCell Line, TumorDNA, MitochondrialFemaleFreezingHumansMass SpectrometryPathology, MolecularPolymerase Chain ReactionPolymorphism, Single NucleotideSensitivity and SpecificitySequence Analysis, DNASpecimen HandlingDNA, Mitochondrial

Identifiers

PMID29396409
PMCPMC5797170
OpenAlexW2806648356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.